Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 61.67

-3.6%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	6/16/2004 9:43:31 AM
From: zeta1961	Read Replies (1) of 52153

APHT G17DT=INSEGIA linguistic cognizante...comments appreciated, can't find an Albanian root:)...impact on valuation?<g> MIAMI, Jun 16, 2004 (BUSINESS WIRE) -- Aphton Corporation (APHT) announced today that it has selected INSEGIA(TM) as the trade name for G17DT, Aphton's product designed to reduce tumor growth and extend survival rates of patients with gastrointestinal cancers. "We believe the selection of the trade name marks a significant step towards the realization of Aphton as a commercial biopharmaceutical company," commented Patrick Mooney, President and CEO of Aphton. "We are excited about this milestone; with our two regulatory filings in Australia and Switzerland and expected phase III data from our clinical trial testing INSEGIA in combination with gemcitabine in patients with advanced pancreatic cancer at the end of 2004, we felt now was the perfect time to name our lead product candidate." Zeta

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next